NCT07065058View on ClinicalTrials.gov

A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

January 31, 2026

Conditions
Obesity &Amp; Overweight
Interventions
DRUG

Drug: VCT220, Repaglinide, Rosuvastatin, and Digoxin

Single dose of Repaglinide at Day 2, Rosuvastatin and Digoxin at Day 3 Orally VCT220 once daily from Day 9 to Day 78, titrated from 20mg to 160mg. Co-administrated Repaglinide at Day 72, co-administrated Rosuvastatin and Digoxin at Day 73

Trial Locations (1)

610041

West China Second University Hospital, Chengdu

All Listed Sponsors
lead

Vincentage Pharma Co., Ltd

INDUSTRY